SurgiMab Phase I clinical trial l

SurgiMab > News & Events > News > First-in-human phase I study for SurgiMab’s molecule SGM-101 launched in Montpellier Cancer Institute > SurgiMab Phase I clinical trial l

18 April 2016 Administrateur SurgiMabLeave a comment0

Previous Post
First-in-human phase I study for SurgiMab’s molecule SGM-101 launched in Montpellier Cancer Institute

Recent Posts

SurgiMab will sponsor the next edition of the International Symposium on Fluorescence Guided Surgery, 2-3 Nov 2023 in Amsterdam
SurgiMab will participate to the conference “Optics in the Life Sciences” during the Optica Biophotonics Congress in Vancouver April 23 – 27, 2023
SurgiMab co-sponsors the Molecular-Guided Surgery meeting that will take place during the SPIE Photonics West conference in San Francisco on Jan 22-23, 2022.
SurgiMab will attend the 7th Annual International Congress for Fluorescence-Guided Surgery – Coral Gables, FL, 15th and 16th feb. 2020.
SurgiMab sponsors the conference “Molecular-Guided Surgery” of the SPIE Photonics West meeting – San Francisco, 1st and 2nd feb. 2020.

Tumor detection Clinical development Company News & Events Contact

About SurgiMab

SurgiMAb develops injectable fluorescent conjugates to be used during Fluorescence-Guided Surgery (FGS) by oncology surgeons so they can clearly delineate tumors and visualize infra-clinical size nodules invisible to their naked eyes.

Latest news

SurgiMab will sponsor the next edition of the International Symposium on Fluorescence Guided Surgery, 2-3 Nov 2023 in Amsterdam
SurgiMab will participate to the conference “Optics in the Life Sciences” during the Optica Biophotonics Congress in Vancouver April 23 – 27, 2023

Home . Legal & credits